MCM6 Antibody (G-8): sc-393463
- MCM6 Antibody (G-8) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- specific for an epitope mapping between amino acids 7-32 at the N-terminus of MCM6 of human origin
- recommended for detection of MCM6 of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for MCM6 Antibody (G-8) for WB applications. These reagents are now offered in bundles with MCM6 Antibody (G-8) (see ordering information below).
MCM6 Antibody (G-8) is a mouse monoclonal IgG1 antibody that detects MCM6 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MCM6, a member of the mini-chromosome maintenance (MCM) protein family, plays a crucial role in the regulation of DNA replication, ensuring that DNA is replicated only once during each cell cycle. This regulation is vital for maintaining genomic stability, as improper replication can lead to mutations and cancer. MCM6, along with other MCM proteins, is expressed at higher levels during cell growth, particularly peaking during the transition from the G1 to S phase of the cell cycle. MCM6 contains an ATP-binding motif that is essential for unwinding double-stranded DNA, a critical step in the replication process. MCM6 interacts with various protein kinases and transcription factors, which modulate activity and stability, further emphasizing importance in cellular processes. Anti-MCM6 antibody (G-8) serves as an invaluable tool for researchers studying the mechanisms of DNA replication and the role of MCM proteins in cell cycle regulation.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
MCM6 Antibody (G-8) References:
- MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression. | Liu, Z., et al. 2018. BMC Cancer. 18: 200. PMID: 29463213
- MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma. | Gu, Y., et al. 2021. BMC Cancer. 21: 784. PMID: 34233647
- Prognostic significance of MCM6 expression in gastrointestinal stromal tumor. | Shim, YR., et al. 2021. Int J Clin Exp Pathol. 14: 1119-1127. PMID: 35027992
- MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers. | Sadeghian, D., et al. 2022. Diagn Pathol. 17: 24. PMID: 35125121
- MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target. | Wang, Y., et al. 2022. Theranostics. 12: 6509-6526. PMID: 36185598
- Benvitimod inhibits MCM6-meditated proliferation of keratinocytes by regulating the JAK/STAT3 pathway. | Cai, Z., et al. 2023. J Dermatol Sci. 109: 71-79. PMID: 36774328
- MCM6 promotes intrahepatic cholangiocarcinoma progression by upregulating E2F1 and enhancing epithelial-mesenchymal transition. | Gao, C., et al. 2023. Carcinogenesis. 44: 279-290. PMID: 37185675
- MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer. | Lei, Z., et al. 2023. Front Biosci (Landmark Ed). 28: 128. PMID: 37664925
- Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis. | Wang, J., et al. 2023. Life Sci. 335: 122253. PMID: 37951536
- Crotonylation of MCM6 enhances chemotherapeutics sensitivity of breast cancer via inducing DNA replication stress. | Song, H., et al. 2025. Cell Prolif. 58: e13759. PMID: 39477811
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MCM6 Antibody (G-8) | sc-393463 | 200 µg/ml | $322.00 | |||
MCM6 Antibody (G-8): m-IgG Fc BP-HRP Bundle | sc-540901 | 200 µg Ab; 10 µg BP | $361.00 | |||
MCM6 Antibody (G-8): m-IgG1 BP-HRP Bundle | sc-542452 | 200 µg Ab; 20 µg BP | $361.00 | |||
MCM6 (G-8) Neutralizing Peptide | sc-393463 P | 100 µg/0.5 ml | $69.00 |